IMS 2023: Multiple myeloma roundup

Share :
Published: 3 Oct 2023
Views: 3272
Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Prof Philippe Moreau speaks to ecancer about the final overall survival analysis of the IKEMA study and discusses the other stand-out multiple myeloma data from the 2023 International Myeloma Society annual conference.

The IKEMA study investigated isatuximab, carfilzomib and dexamethasone compared to carfilzomib and dexamethasone in patients with relapsed multiple myeloma.

The final overall survival analysis of this study showed a meaningful trend for overall survival benefit with Isatuximab, carfilzomib and dexamethasone compared to carfilzomib and dexamethasone only despite subsequent treatment with anti-CD38 agents, other agents, and the COVID-19 pandemic.

Prof Moreau also talks about the results from the phase 3 CANOVA study of venetoclax versus pomalidomide added to dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.

He further mentions the results of a phase 2 study of venetoclax in combination with carfilzomib-dexamethasone compared to carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma.

Prof Moreau also highlights the GMMG-CONCEPT trial and the phase 2 study by the IFM 2018-04 group.

He concludes by discussing the pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide refractory multiple myeloma in the CARTITUDE-4 trial.

Phase 2 study compares Venetoclax+Carfilzomib-Dexamethasone to Carfilzomib-Dexamethasone in t(11;14) multiple myeloma patients
IFM 2018-04 Study


ecancer's filming has been kindly supported by Sanofi through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.